Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
Pharmaceutical Executive November 1, 2005 Patrick Clinton	From the Editor: Lost World Leo Sternbach was an extraordinary individual, whose death feels like the end of an era in pharmaceuticals.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Chemistry World September 12, 2012 Jon Evans	Drawing maps to hunt for biological gold Pharmaceutical companies should pay more attention to traditional medicine, say UK researchers. This follows their discovery that genetically-similar plants have traditionally been used to treat the same conditions in widely separated parts of the world.
Salon.com March 9, 2000 Lawrence H. Diller, M.D.	Kids on drugs A behavioral pediatrician questions the wisdom of medicating our children.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
Nursing May 2012 Tim Blake	Three Medication Pathways for Bipolar Disorder No matter where you work, you're likely to care for patients with bipolar disorder, which affects about 2.6% of people age 18 and older per year.
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
Wired September 25, 2007 Patrick Di Justo	From Benzedrine to Abilify, Chronicling America's Love of Psychiatric Drugs A history of what Americans have used to battle depression.
Chemistry World June 2006 Philip Ball	Chancing Upon Chemical Wonders Serendipity has played a big part in many of chemistry's major discoveries, from electrically conducting polymers to mauve dye. Here the author shows how anyone can make a mistake, but it takes a special sort of person to draw gold from the dross.
Chemistry World March 27, 2014 Derek Lowe	Known unknowns Most dangerous substances announce themselves by their structures and reactivity, and a competent organic chemist should be able to read those signs.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World July 21, 2010 Lewis Brindley	Selenium-based quinones show anticancer promise The new compounds have great potential for future cancer therapy, and early studies show similar activity to the well-known chemotherapy drug cisplatin, although a selenium-based therapy would cost a fraction of the price.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Chemistry World May 2007 Lisa Melton	Chinese Medicine in Western Packaging The past decade has seen a global awakening to the truly curative powers of many ancient medicines, from black bear bile to the Asian plant Epimedium.
Bio-IT World February 10, 2003 Malorye Branca	Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.
Food Processing March 2009 Diane Toops	Kraft Foods Global Thinks Outside the Box with Bioactive Ingredients Kraft hires a pharmaceutical company to help it develop functional foods.
Pharmaceutical Executive September 1, 2005 Parker & Amar	Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
Chemistry World May 26, 2011 Rebecca Brodie	Nanospray for nanodrugs Teams from the US and Germany have developed a spray drying technique to fabricate drug formulations smaller than 100nm for pharmaceutical trials, improving the drugs' solubility, or bioavailability.
Chemistry World January 2012	Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool May 25, 2007 Brian Orelli	Amylin Sifts for Gold The biotech mines extra value from its compound library. Investors, take note.
Salon.com October 4, 2000 Kuhn & Wilson	The zitty face of depression Drugs for depression and drugs for acne don't always mix well...
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World March 27, 2013 Eugene Gerden	Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
Chemistry World March 7, 2011 Russell Johnson	Breathe out for personalised medicine A method to analyse drug levels in the body could allow people with epilepsy to avoid weeks of blood tests, claim scientists from Switzerland.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
Nursing February 2010 Jeanne Held-Warmkessel	How to prevent and manage Tumor lysis syndrome Potentially fatal, tumor lysis syndrome is a metabolic disturbance caused by the death of cancer cells during cancer treatment and the release of their intracellular components into the bloodstream.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Chemistry World June 18, 2015 Emma Stoye	Crowdsourcing compounds to tackle antibiotic resistance Chemists around the world are being called on to donate samples of novel compounds they have synthesized to a crowdsourcing project that aims to find new antibiotics.
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
ifeminists November 17, 2004 Byron Fraser	Review: Your Drug May Be Your Problem Excerpts from the book Your Drug May Be Your Problem: How and Why to Stop Taking Psychiatric Medications by Peter Breggin and David Cohen delineating the adverse effects of these medications and how to stop taking them.
BusinessWeek April 18, 2005	Making Those Pills Safe For Kids Few medicines get tested on children. Dr. Donald Mattison is pushing to change that.
Chemistry World March 10, 2006	Dual Organometallics Enhance Zinc Reactivity Chemists have synthesised organometallic compounds that enable zinc to participate in directed metalation of organic substrates.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
American Family Physician March 1, 2004	Chronic Pain Medicines Description of the different types of pain medicines for chronic pain.
Chemistry World June 23, 2010 Sarah Houlton	A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines.
American Family Physician September 15, 2000 Kim S. Griswold, M.D., M.P.H. & Linda F. Pessar, M.D.	Management of Bipolar Disorder A comprehensive management program, including collaboration between the patient's family physician and psychiatrist, should be implemented to optimize medical care...